The GDF15-GFRAL Pathway in Health and Metabolic Disease: Friend or Foe?
- PMID: 33228454
- DOI: 10.1146/annurev-physiol-022020-045449
The GDF15-GFRAL Pathway in Health and Metabolic Disease: Friend or Foe?
Abstract
GDF15 is a cell activation and stress response cytokine of the glial cell line-derived neurotrophic factor family within the TGF-β superfamily. It acts through a recently identified orphan member of the GFRα family called GFRAL and signals through the Ret coreceptor. Cell stress and disease lead to elevated GDF15 serum levels, causing anorexia, weight loss, and alterations to metabolism, largely by actions on regions of the hindbrain. These changes restore homeostasis and, in the case of obesity, cause a reduction in adiposity. In some diseases, such as advanced cancer, serum GDF15 levels can rise by as much as 10-100-fold, leading to an anorexia-cachexia syndrome, which is often fatal. This review discusses how GDF15 regulates appetite and metabolism, the role it plays in resistance to obesity, and how this impacts diseases such as diabetes, nonalcoholic fatty liver disease, and anorexia-cachexia syndrome. It also discusses potential therapeutic applications of targeting the GDF15-GFRAL pathway and lastly suggests some potential unifying hypotheses for its biological role.
Keywords: GDF15; GDNF; GFRAL; GFRα; MIC-1; Ret; TGF-β superfamily; anorexia-cachexia; appetite; area postrema; metabolism; nucleus of the solitary tract; obesity.
Similar articles
-
The MIC-1/GDF15-GFRAL Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other Associated Diseases.Cell Metab. 2018 Sep 4;28(3):353-368. doi: 10.1016/j.cmet.2018.07.018. Cell Metab. 2018. PMID: 30184485 Review.
-
Targeting Obesity and Cachexia: Identification of the GFRAL Receptor-MIC-1/GDF15 Pathway.Trends Mol Med. 2017 Dec;23(12):1065-1067. doi: 10.1016/j.molmed.2017.10.005. Epub 2017 Nov 9. Trends Mol Med. 2017. PMID: 29129392
-
GDF15 mediates adiposity resistance through actions on GFRAL neurons in the hindbrain AP/NTS.Int J Obes (Lond). 2019 Dec;43(12):2370-2380. doi: 10.1038/s41366-019-0365-5. Epub 2019 May 31. Int J Obes (Lond). 2019. PMID: 31152154
-
Insights Into Mechanisms of GDF15 and Receptor GFRAL: Therapeutic Targets.Trends Endocrinol Metab. 2020 Dec;31(12):939-951. doi: 10.1016/j.tem.2020.10.004. Epub 2020 Nov 7. Trends Endocrinol Metab. 2020. PMID: 33172749 Review.
-
GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates.Nat Med. 2017 Oct;23(10):1150-1157. doi: 10.1038/nm.4392. Epub 2017 Aug 28. Nat Med. 2017. PMID: 28846097
Cited by
-
Growth differentiation factor-15 may be a novel biomarker in pancreatic cancer: A review.Medicine (Baltimore). 2024 Feb 9;103(6):e36594. doi: 10.1097/MD.0000000000036594. Medicine (Baltimore). 2024. PMID: 38335385 Free PMC article. Review.
-
Relationships between Circulating Biomarkers and Body Composition Parameters in Patients with Metabolic Syndrome: A Community-Based Study.Int J Mol Sci. 2024 Jan 10;25(2):881. doi: 10.3390/ijms25020881. Int J Mol Sci. 2024. PMID: 38255954 Free PMC article.
-
Serum-based biomarkers associated with lung cancer risk and cause-specific mortality in the German randomized Lung Cancer Screening Intervention (LUSI) trial.Transl Lung Cancer Res. 2023 Dec 26;12(12):2460-2475. doi: 10.21037/tlcr-23-548. Epub 2023 Dec 22. Transl Lung Cancer Res. 2023. PMID: 38205209 Free PMC article.
-
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges.Drugs. 2023 Dec 21. doi: 10.1007/s40265-023-01982-6. Online ahead of print. Drugs. 2023. PMID: 38127286 Review.
-
A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia.Clin Cancer Res. 2024 Feb 1;30(3):489-497. doi: 10.1158/1078-0432.CCR-23-1631. Clin Cancer Res. 2024. PMID: 37982848 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
